HRP20160399T1 - Sulfonamidi, namijenjeni sprječavanju dijabetesa - Google Patents

Sulfonamidi, namijenjeni sprječavanju dijabetesa Download PDF

Info

Publication number
HRP20160399T1
HRP20160399T1 HRP20160399TT HRP20160399T HRP20160399T1 HR P20160399 T1 HRP20160399 T1 HR P20160399T1 HR P20160399T T HRP20160399T T HR P20160399TT HR P20160399 T HRP20160399 T HR P20160399T HR P20160399 T1 HRP20160399 T1 HR P20160399T1
Authority
HR
Croatia
Prior art keywords
diabetes
prevention
compound
sulfonamides
trifluoromethanesulfonyloxy
Prior art date
Application number
HRP20160399TT
Other languages
English (en)
Croatian (hr)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S.P.A. filed Critical Dompé Farmaceutici S.P.A.
Publication of HRP20160399T1 publication Critical patent/HRP20160399T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20160399TT 2009-10-06 2010-10-06 Sulfonamidi, namijenjeni sprječavanju dijabetesa HRP20160399T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
EP10768898.8A EP2485724B1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
HRP20160399T1 true HRP20160399T1 (hr) 2016-05-20

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160399TT HRP20160399T1 (hr) 2009-10-06 2010-10-06 Sulfonamidi, namijenjeni sprječavanju dijabetesa

Country Status (24)

Country Link
US (2) US8846755B2 (enExample)
EP (2) EP2308485A1 (enExample)
JP (1) JP5745526B2 (enExample)
KR (1) KR101737656B1 (enExample)
CN (1) CN102639128B (enExample)
AU (1) AU2010305384B2 (enExample)
BR (1) BR112012007989B1 (enExample)
CA (1) CA2776021C (enExample)
CY (1) CY1117599T1 (enExample)
DK (1) DK2485724T3 (enExample)
EA (1) EA021788B1 (enExample)
ES (1) ES2570463T3 (enExample)
HR (1) HRP20160399T1 (enExample)
HU (1) HUE028132T2 (enExample)
IL (1) IL219038A (enExample)
ME (1) ME02385B (enExample)
MX (1) MX2012004087A (enExample)
NZ (1) NZ599171A (enExample)
PL (1) PL2485724T3 (enExample)
RS (1) RS54693B1 (enExample)
SI (1) SI2485724T1 (enExample)
SM (1) SMT201600126B (enExample)
WO (1) WO2011042465A1 (enExample)
ZA (1) ZA201202462B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
EP4686469A1 (en) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
DE602004003673T2 (de) 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
KR20110014141A (ko) * 2008-03-20 2011-02-10 카롤러스 테라퓨틱스, 인코포레이티드 염증을 치료하는 방법
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes

Also Published As

Publication number Publication date
PL2485724T3 (pl) 2016-07-29
BR112012007989B1 (pt) 2019-10-22
SI2485724T1 (sl) 2018-12-31
KR101737656B1 (ko) 2017-05-18
NZ599171A (en) 2014-03-28
AU2010305384A1 (en) 2012-04-26
CA2776021C (en) 2017-08-01
ES2570463T3 (es) 2016-05-18
ZA201202462B (en) 2013-06-26
US20150011639A1 (en) 2015-01-08
US20130059908A1 (en) 2013-03-07
ME02385B (me) 2016-09-20
CA2776021A1 (en) 2011-04-14
US8846755B2 (en) 2014-09-30
US9556115B2 (en) 2017-01-31
EP2485724B1 (en) 2016-02-10
DK2485724T3 (en) 2016-05-02
RS54693B1 (sr) 2016-08-31
CN102639128A (zh) 2012-08-15
IL219038A (en) 2015-07-30
JP2013506703A (ja) 2013-02-28
KR20120083889A (ko) 2012-07-26
SMT201600126B (it) 2016-07-01
AU2010305384B2 (en) 2016-02-04
EA021788B1 (ru) 2015-08-31
EA201270512A1 (ru) 2012-11-30
EP2308485A1 (en) 2011-04-13
CY1117599T1 (el) 2017-04-26
CN102639128B (zh) 2014-02-26
EP2485724A1 (en) 2012-08-15
WO2011042465A1 (en) 2011-04-14
JP5745526B2 (ja) 2015-07-08
HUE028132T2 (en) 2016-11-28
MX2012004087A (es) 2012-08-23
IL219038A0 (en) 2012-06-28
HK1174557A1 (en) 2013-06-14

Similar Documents

Publication Publication Date Title
NZ607794A (en) N-acylsulfonamide apoptosis promoters
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
HRP20120323T1 (en) Diarylhydantoin compounds
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
NZ603198A (en) Novel hydroxamic acid derivative
HRP20180528T1 (hr) Derivati naftiridina, korisni kao antagonisti alfa-v-beta-6 integrina
ME02558B (me) Inhibitori replikacije virusa gripa
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
WO2014068402A3 (en) Pharmaceutical formulation containing thienotriazolodiazepine compounds
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
ME02729B (me) Indolski i indazolski spojevi koji aktiviraju ampk
AR057894A1 (es) Derivados de tiofeno
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
HRP20161103T1 (hr) Kemijski spojevi
NZ596431A (en) Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
IL225400A0 (en) Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
HRP20160291T1 (hr) Soli od n-hidroksi-3-(4-(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
HRP20171058T1 (hr) Derivati dipeptida lizinske glutaminske kiseline
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
ME02385B (me) Sulfonamidi za prevenciju dijabetesa